Therapeutic Targeting of the Anaplastic Lymphoma Kinase (ALK) in Neuroblastoma—A Comprehensive Update
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic Targeting of the Anaplastic Lymphoma Kinase (ALK) in Neuroblastoma—A Comprehensive Update
Authors
Keywords
-
Journal
Pharmaceutics
Volume 13, Issue 9, Pages 1427
Publisher
MDPI AG
Online
2021-09-08
DOI
10.3390/pharmaceutics13091427
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Activated ALK Cooperates with N-Myc via Wnt/β-catenin Signaling to Induce Neuroendocrine Prostate Cancer
- (2021) Kenji Unno et al. CANCER RESEARCH
- Activity of Crizotinib in Patients with ALK-aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)
- (2021) Jennifer H Foster et al. CLINICAL CANCER RESEARCH
- ERK/MAPK signalling pathway and tumorigenesis (Review)
- (2020) Yan‑Jun Guo et al. Experimental and Therapeutic Medicine
- Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study.
- (2020) Kelly C. Goldsmith et al. JOURNAL OF CLINICAL ONCOLOGY
- mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
- (2020) Zhilin Zou et al. Cell and Bioscience
- Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
- (2019) Raghav Dogra et al. Anti-Cancer Agents in Medicinal Chemistry
- Combined Inhibition of ALK and HDAC Induces Synergistic Cytotoxicity in Neuroblastoma Cell Lines
- (2019) KAZUMI HAGIWARA et al. ANTICANCER RESEARCH
- A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas
- (2019) Chia-Chi Lin et al. BRITISH JOURNAL OF CANCER
- A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma
- (2019) Tim van Groningen et al. Nature Communications
- Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
- (2019) Muhammad Wasi Alam et al. Frontiers in Oncology
- The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors
- (2019) Helei Hou et al. Cancer Cell International
- Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
- (2019) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)
- (2019) Xiaotian Kong et al. JOURNAL OF MEDICINAL CHEMISTRY
- Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model
- (2019) Suzanne P. MacFarland et al. MOLECULAR CANCER THERAPEUTICS
- Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells
- (2019) Diana Cervantes-Madrid et al. Scientific Reports
- Origin and initiation mechanisms of neuroblastoma
- (2018) Shoma Tsubota et al. CELL AND TISSUE RESEARCH
- Genetic susceptibility to neuroblastoma: current knowledge and future directions
- (2018) Laura E. Ritenour et al. CELL AND TISSUE RESEARCH
- Neuroblastoma
- (2018) Akira Nakagawara et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Role and targeting of anaplastic lymphoma kinase in cancer
- (2018) Carminia Maria Della Corte et al. Molecular Cancer
- Good clinical response to alectinib, a second generation ALK inhibitor, in refractory neuroblastoma
- (2018) John A. Heath et al. PEDIATRIC BLOOD & CANCER
- Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer
- (2018) Sara Redaelli et al. CANCER RESEARCH
- Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
- (2018) Holly L Pacenta et al. Drug Design Development and Therapy
- Overview and recent advances in the treatment of neuroblastoma
- (2017) Sarah B. Whittle et al. Expert Review of Anticancer Therapy
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
- (2017) Alexander Drilon et al. Cancer Discovery
- Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models
- (2017) Hui Qin Wang et al. eLife
- Combating Drug-Resistant Mutants of Anaplastic Lymphoma Kinase with Potent and Selective Type-I1/2 Inhibitors by Stabilizing Unique DFG-Shifted Loop Conformation
- (2017) Peichen Pan et al. ACS Central Science
- The role of the ALK receptor in cancer biology
- (2016) B. Hallberg et al. ANNALS OF ONCOLOGY
- Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
- (2016) Andrew C. Wood et al. CLINICAL CANCER RESEARCH
- The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN
- (2016) J. Guan et al. Disease Models & Mechanisms
- First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors
- (2016) Tianhong Li et al. Journal of Hematology & Oncology
- Pyrazolylamine Derivatives Reveal the Conformational Switching between Type I and Type II Binding Modes of Anaplastic Lymphoma Kinase (ALK)
- (2016) Chih-Hsiang Tu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)
- (2016) Gregory R. Ott et al. JOURNAL OF MEDICINAL CHEMISTRY
- Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
- (2016) E. Ardini et al. MOLECULAR CANCER THERAPEUTICS
- Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice
- (2016) Joachim T. Siaw et al. Oncotarget
- Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis
- (2016) Yongfeng Wang et al. Scientific Reports
- Neuroblastoma: Molecular Pathogenesis and Therapy
- (2015) Chrystal U. Louis et al. Annual Review of Medicine
- Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies
- (2015) Y. P. Mosse CLINICAL CANCER RESEARCH
- Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
- (2015) I. Lambertz et al. CLINICAL CANCER RESEARCH
- Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions
- (2015) Laird Cameron et al. DRUGS
- Advances in Risk Classification and Treatment Strategies for Neuroblastoma
- (2015) Navin R. Pinto et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel ALK inhibitors in clinical use and development
- (2015) Chaitanya Iragavarapu et al. Journal of Hematology & Oncology
- Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
- (2015) Thomas F Eleveld et al. NATURE GENETICS
- ALK inhibitor resistance in ALKF1174L-driven neuroblastoma is associated with AXL activation and induction of EMT
- (2015) D N Debruyne et al. ONCOGENE
- A historical overview of protein kinases and their targeted small molecule inhibitors
- (2015) Robert Roskoski PHARMACOLOGICAL RESEARCH
- The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma
- (2015) N. R. Infarinato et al. Cancer Discovery
- New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK
- (2015) Daniela Di Paolo et al. Oncotarget
- Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells
- (2015) Sanja Aveic et al. Oncotarget
- Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma
- (2015) Nathan F. Moore et al. Oncotarget
- Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma
- (2014) Fei Xu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma
- (2014) Scott C. Bresler et al. CANCER CELL
- Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases
- (2014) Tatsushi Kodama et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non-Small Cell Lung Cancer Model Mice
- (2014) M. Mori et al. MOLECULAR CANCER THERAPEUTICS
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
- (2014) L. Friboulet et al. Cancer Discovery
- Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
- (2013) Yael P Mossé et al. LANCET ONCOLOGY
- The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line
- (2013) Bin Yi et al. TUMOR BIOLOGY
- Biology of the TAM Receptors
- (2013) G. Lemke Cold Spring Harbor Perspectives in Biology
- ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma
- (2013) Md. Kamrul Hasan et al. Scientific Reports
- Neuroblastoma and MYCN
- (2013) M. Huang et al. Cold Spring Harbor Perspectives in Medicine
- Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project
- (2012) G Schleiermacher et al. BRITISH JOURNAL OF CANCER
- The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma
- (2012) Teeara Berry et al. CANCER CELL
- Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis
- (2012) Shizhen Zhu et al. CANCER CELL
- The R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma Kinase
- (2012) Linda F. Epstein et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Rapid Development of Piperidine Carboxamides as Potent and Selective Anaplastic Lymphoma Kinase Inhibitors
- (2012) Marian C. Bryan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells
- (2012) C Schönherr et al. ONCOGENE
- Epithelial to mesenchymal transition: New and old insights from the classical neural crest model
- (2012) Pablo H. Strobl-Mazzulla et al. SEMINARS IN CANCER BIOLOGY
- The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
- (2011) Arvin C. Dar et al. Annual Review of Biochemistry
- CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
- (2011) Hiroshi Sakamoto et al. CANCER CELL
- Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project
- (2011) Wendy B. London et al. JOURNAL OF CLINICAL ONCOLOGY
- Guidelines for Imaging and Staging of Neuroblastic Tumors: Consensus Report from the International Neuroblastoma Risk Group Project
- (2011) Hervé J. Brisse et al. RADIOLOGY
- Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma
- (2011) S. C. Bresler et al. Science Translational Medicine
- Emerging importance of ALK in neuroblastoma
- (2011) Anna M. Azarova et al. SEMINARS IN CANCER BIOLOGY
- All-trans retinoic acid downregulates ALK in neuroblastoma cell lines and induces apoptosis in neuroblastoma cell lines with activated ALK
- (2010) Hitoyasu Futami et al. CANCER LETTERS
- Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification
- (2010) S. De Brouwer et al. CLINICAL CANCER RESEARCH
- BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review
- (2010) Xin An et al. LEUKEMIA RESEARCH
- Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation
- (2009) Fabio Zuccotto et al. JOURNAL OF MEDICINAL CHEMISTRY
- The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report
- (2008) Tom Monclair et al. JOURNAL OF CLINICAL ONCOLOGY
- The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
- (2008) Susan L. Cohn et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of ALK as a major familial neuroblastoma predisposition gene
- (2008) Yaël P. Mossé et al. NATURE
- Activating mutations in ALK provide a therapeutic target in neuroblastoma
- (2008) Rani E. George et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search